It is in the Nature publication
Hit the full size tab Hope this helps.
Could I however suggest that one should be very careful making conclusions on this data. The Clinical response has been shown to be a very poor indication of long-term survival. Also remember that this is a open label trial and the patients gravely ill. Most Dr's would be looking for a response. This effect is one of the primary reasons that regulators don't like open label trials.
Good luck all.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
-0.020(11.8%) |
Mkt cap ! $33.89M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 15.0¢ | $101.9K | 619.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 153571 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 12550 | 1 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |